Prognostic Role of Patient, Tumour and Radiomic Factors Influencing Outcomes in Dogs With Thyroid Cancer Treated With Iodine‐131
Veterinary and Comparative Oncology · 2025
DOI: 10.1111/vco.13070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2025. Verfasst von Ibrahim Chamseddine und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Dog Diseases, Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Dubai Harvard Foundation for Medical Research, NIH HHS.
Abstract (Originalsprache)
Radioactive iodine therapy (I‐131) is widely used in both human and veterinary medicine for treating thyroid cancer, utilising the common biological behaviour of thyroid tissues. Recognising the need to better understand the prognostic factors affecting heterogeneous treatment outcomes, this retrospective study analysed 32 dogs with thyroid carcinoma treated at the University of Missouri Veterinary Health Center. The study examined variables such as patient demographics, tumour characteristics, and first‐order radiomic features. Purposeful feature selection was employed to identify both significant and confounding factors, with a focus on treatment response and survival time. Specific administered activity (SAA) emerged as a significant predictor of treatment response, with higher SAA levels improving odds of response ( p value = 0.02, OR = 10.28), while clinical signs and nodal stage (N‐stage) were identified as significant confounders. Moreover, metastasis stage (M‐stage) ( p < 0.01, OR = 0.35) and tumour‐to‐salivary gland dose uptake ratio (TSGR) significantly affected survival time ( p = 0.02, OR = 1.57), with TSGR displaying a notable nonlinear effect. These results underline the importance of refined patient stratification and highlight the potential for personalised dose adjustments to enhance outcomes in canine thyroid cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- University of Missouri Veterinary Health Center, Columbia, Missouri, USA.
- Departments of Nuclear Engineering and Chemistry, University of California Berkeley, Berkley, California, USA.
ORCID-Profile: Ibrahim Chamseddine, Alejandro Bertolet, Charles A Maitz
Förderung
- NCI NIH HHS
- Dubai Harvard Foundation for Medical Research
- NIH HHS
- National Institutes of Health
Zitieren
APA
Chamseddine, I., Cowan, C., Donnelly, L., Abergel, R. J., Schuemann, J., Bertolet, A., & Maitz, C. A. (2025). Prognostic Role of Patient, Tumour and Radiomic Factors Influencing Outcomes in Dogs With Thyroid Cancer Treated With Iodine‐131. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.13070
Vancouver
Chamseddine I, Cowan C, Donnelly L, Abergel RJ, Schuemann J, Bertolet A, et al. Prognostic Role of Patient, Tumour and Radiomic Factors Influencing Outcomes in Dogs With Thyroid Cancer Treated With Iodine‐131. Veterinary and Comparative Oncology. 2025. doi:10.1111/vco.13070
BibTeX
@article{Chamseddine2025,
author = {Chamseddine, Ibrahim and Cowan, Caitlin and Donnelly, Lindsay and Abergel, Rebecca J and Schuemann, Jan and Bertolet, Alejandro and Maitz, Charles A},
title = {Prognostic Role of Patient, Tumour and Radiomic Factors Influencing Outcomes in Dogs With Thyroid Cancer Treated With Iodine‐131},
journal = {Veterinary and Comparative Oncology},
year = {2025},
doi = {10.1111/vco.13070}
}
EUVIMED